Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
cervical%20cancer%20-%20prevention%20-and-%20screening
CERVICAL CANCER - PREVENTION & SCREENING
Mortality due to cervical cancer can be reduced by prevention, early detection & treatment.
Vaccination may be started as early as 9 years old.
Vaccination may reduce the incidence of HPV-related disease.
Screening for cervical cancer after vaccination is still recommended because only 70% of the virus types associated w/ invasive cervical cancer consist of HPV 16 & 18 types & women may not be entirely protected if they have been infected w/ other HPV types prior to vaccination.
Drug Information

Indication: Prevention of cervical, vulvar, vag cancer, precancerous or dysplastic lesions & genital warts caused by H...

Indication: Prevention of cervical, vulvar, vag cancer; precancerous or dysplastic lesions & genital warts caused by h...

Indication: Prevention of premalignant genital lesions & cervical cancer caused by human papillomavirus types 16 &...

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Olaparib improves response, PFS over chemo in relapsed, BRCA mutated, platinum-sensitive ovarian cancer
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving ≥2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.
Netupitant‐palonosetron combo prevents chemo-induced nausea, vomiting
Audrey Abella, 09 Jul 2019
A fixed single‐dose of netupitant 300 mg plus palonosetron 0.50 mg (NEPA) was better than palonosetron and aprepitant in preventing acute and delayed* chemotherapy-induced nausea and vomiting (CINV) following multiple chemotherapy cycles, according to the results of two phase III trials.